Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time

Article activity feed

1. Version published to 10.1128/mbio.03442-21

   Feb 22, 2022
2. 

   ScreenIT

   Aug 28, 2021

   SciScore for 10.1101/2021.08.22.21262186: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: Human subjects and samples: Ethical approval: This study was approved by the central ethics committee of Buenos Aires province, Consent: All participants provided written informed consent prior to collection of data and specimen (Cod#2021-00983502). IACUC: Work with SARS-CoV-2 was approved by the INBIRS Institutional Biosafety Committee at Biosafety level 3 with negative pressure.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   METHOD DETAILS: SARS-CoV-2 antibody ELISA: Antibodies to SARS-CoV-2 spike protein were detected using an …

   SciScore for 10.1101/2021.08.22.21262186: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: Human subjects and samples: Ethical approval: This study was approved by the central ethics committee of Buenos Aires province, Consent: All participants provided written informed consent prior to collection of data and specimen (Cod#2021-00983502). IACUC: Work with SARS-CoV-2 was approved by the INBIRS Institutional Biosafety Committee at Biosafety level 3 with negative pressure.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   METHOD DETAILS: SARS-CoV-2 antibody ELISA: Antibodies to SARS-CoV-2 spike protein were detected using an established two step ELISA previously described (Ojeda et al., 2021).	SARS-CoV-2 spike protein suggested: None
   Comparison of antibody concentration, neutralizing titer and neutralizing potency index were done using the Wilcoxon matched paired test in Figures 1C, 1D. 1E, 2A, 2B, 3A, 3B and S1.	S1 suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Cell lines: Vero E6, Vero-CCL81, Vero E6-TMPRSS2, or Vero-hACE2-TMPRSS2 cells (ATCC) and 293T ACE2/TMPRSS2 cells, kindly provided by Dr. Benhur Lee, were cultured at 37ºC in 5% CO2 in Dulbecco’s Modified Eagle’s high glucose medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS)(GIBCO).	Vero E6 suggested: RRID:CVCL_XD71) Vero-hACE2-TMPRSS2 suggested: None
   Recombinant VSV: Briefly, recombinant VSVs were rescued by infecting BSRT7/5 cells with vaccinia virus vTF7-3 and subsequently transfecting them with T7-driven support plasmids encoding VSV N, P, L, G, and VSV genomic cDNAs.	BSRT7/5 suggested: CCLV Cat# CCLV-RIE 0583, RRID:CVCL_RW96)
   Working stocks were generated on Vero-CCL81 or Vero E6-TMPRSS2 cells at 34°C.	Vero E6-TMPRSS2 suggested: None
   Viral stocks (VSV-eGFP-SARS-CoV-2), generated in Sean Whelan laboratory, were amplified in our laboratory using 293T ACE2/TMPRSS2 cells at an MOI of 0.01 in Dulbecco’s Modified Eagle’s medium containing 2% FBS at 37ºC.	ACE2/TMPRSS2 suggested: None
   Vero cells were used for these assays.	Vero suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
   Software and Algorithms
   Sentences	Resources
   Viruses: SARS-CoV-2	SARS-CoV-2 suggested: (BioLegend Cat# 946101, RRID:AB_2892515)
   Absolute inhibitory concentrations (absIC) values were calculated for all patient sera samples by modeling a 4-parameter logistic (4PL) regression with GraphPad Prism 8.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a protocol registration statement.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.08.22.21262186 on medRxiv

   Aug 25, 2021